MiMedx Group Inc (MDXG) Stock Analysis
Verdict: WATCH (do not buy)
High gross margins and $166.1M cash cushion valuation risk, but consecutive quarterly earnings misses limit upside.
Investment score: 51/100
Analysis as of
Is MiMedx Group Inc stock worth reviewing? The TradeMates thesis
MiMedx balances strong balance sheet cash ($166.12M) and high gross margins (78.85%) against recent quarterly operational losses that inflate trailing P/E to 117.50x.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 65/100 (weight 15%)
- Technical Momentum: 55/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
MiMedx Group Inc opportunities and risks
What speaks for MDXG
- Strong Liquidity and Net Cash Position
What speaks against MDXG
- Recent Quarterly Earnings Degradation
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| MDXG | 117.5x | 1.9x | 23.2x | 78.8% | 1.8% | 5.9% |
| NVCT | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.3% |
| GYRE | n/a | 6.5x | n/a | 94.3% | -14.5% | -2.2% |
| AURA | n/a | 0.0x | n/a | 0.0% | 0.0% | -14.6% |
| NGNE | n/a | 0.0x | n/a | 0.0% | 0.0% | -15.5% |
| IRWD | 5.4x | 1.8x | 4.2x | 99.8% | 33.4% | 26.2% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.3% |
Frequently asked questions about MiMedx Group Inc (MDXG)
Is MDXG stock a good investment?
The TradeMates model rates MiMedx Group Inc as WATCH (do not buy) with an investment score of 51/100. MiMedx balances strong balance sheet cash ($166.12M) and high gross margins (78.85%) against recent quarterly operational losses that inflate trailing P/E to 117.50x. This is algorithmic model output, not personal investment advice.
Is MDXG stock a buy?
The TradeMates model verdict for MDXG is WATCH (do not buy) with an investment score of 51/100. Treat this as a model signal to review, not a personal buy recommendation.